LAG-3 has rapidly progressed from a specialized immunological concept to a prominent research focus in oncology, immuno-oncology therapeutic combinations, and autoimmune disease studies. As attention toward immune checkpoints beyond PD-1/PD-L1 intensifi ...
もっと読む
2025年10月
Expanding Horizons of MET Kinase Inhibitors
The MET receptor pathway has solidified its position as a critical focus area in contemporary oncology, attracting substantial research funding and commercial investment. As precision medicine continues to mature, MET inhibitors are demonstrating their ...
もっと読む
